Advancement of the study into the Phase 2 expansion follows the successful completion of the Phase 1 dose escalation portion of the trial, where 1.0 mg of tivozanib was administered for 21 days ...
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new efficacy and safety data from the first ...
AVEO Oncology (formerly known as AVEO Pharmaceuticals) announced the presentation of results from the phase 1b portion of the phase 1b/2 DEDUCTIVE clinical trial of tivozanib (Fotivda), AVEO’s ...
ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the ...
BOSTON--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results